Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Job Cuts Seen At Dr Reddy’s Amid Cost Recalibration

Fri, 07/13/2018 - 1:49pm

Dr Reddy’s Laboratories has set in motion significant cost control initiatives as part of broader efforts to emerge leaner and...

      Related Stories 

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

Fri, 07/13/2018 - 1:44pm

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses...

      Related Stories 

Roivant Splashes Cash Again To License GSK Skin Disorder Drug

Fri, 07/13/2018 - 8:44am

The UK drug maker is tightening its R&D focus by selling on the psoriasis and atopic dermatitis investigational drug tapinarof...

      Related Stories 

Pharma Q2 Results Preview: Johnson & Johnson And Novartis

Fri, 07/13/2018 - 7:57am

The earnings season is on us again with two of the heavyweights of healthcare hoping to show strong second-quarter results...

      Related Stories 

Pipeline Watch: Phase III Starts With QPI-1002, Enfortumab Vedotin And ZYN-002

Fri, 07/13/2018 - 6:18am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Authorities Find Accounting Violation By Samsung BioLogics, Prosecutors To Probe

Thu, 07/12/2018 - 11:57pm

South Korean financial authorities conclude Samsung BioLogics violated accounting standards by omitting certain information on its joint venture agreement with Biogen...

      Related Stories 

Zogenix' ZX008 Emerges As Strong Contender In Rare Epilepsy

Thu, 07/12/2018 - 3:17pm

Strong efficacy and a clean safety profile – with no cardiovascular signal – in another Phase III study bode well...

      Related Stories 

Genmab Moves On From Darzalex/Tecentriq Failure With Bispecifics Deal

Thu, 07/12/2018 - 8:34am

Genmab is planning for its post-Darzalex future by exploring bispecific immunotherapies in a collaboration with Immatics that should see it...

      Related Stories 

Alarm As Novartis Exits Antibiotics Space

Thu, 07/12/2018 - 7:45am

The Swiss major says that while the science for its antibacterial and antiviral research programs is compelling, "we have decided...

      Related Stories 

Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic

Thu, 07/12/2018 - 4:03am

Spun out from Oculeve in tandem with that company’s acquisition by Allergan, Oyster Point hopes to develop a nasal spray...

      Related Stories 

Pages